IPO registrations (S-1, F-1) · Registrants
REVIVA PHARMACEUTICALS HOLDINGS, INC.
- SEC CIK
- 1742927 · filings on EDGAR ↗
- Former names
- Tenzing Acquisition Corp. (2018–2020)
- Registration
- Form S-1, first filed 2018-07-20, last 2022-10-06; 4 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2018-08-22; declared effective 2018-08-20
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 10080 N WOLFE ROAD, SUITE SW3-200, Cupertino, CA 95014
- Ticker
- RVPH (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- REVIVA PHARMACEUTICALS HOLDINGS, INC. on the corporate pages
Offering terms
- Final price
- $10.00 per share (424B4 filed 2018-08-22, an initial public offering)
- Shares sold
- 5,500,000
- Gross proceeds
- $55,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol TZAC
- Lead underwriters
- Maxim Group
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: REVIVA PHARMACEUTICALS HOLDINGS INC Fuzzy (name and state)
- Form D issuer: REVIVA PHARMACEUTICALS HOLDINGS, INC. EXACT (CIK (EXACT))
- SEC filer: REVIVA PHARMACEUTICALS HOLDINGS, INC. EXACT (CIK (EXACT))
Filings 31
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2018-07-20 | S-1 | S-1 (registration) | Tenzing Acquisition Corp. | 0001144204-18-039143 ↗ |
| 2018-08-06 | S-1/A | S-1/A (amendment) | Tenzing Acquisition Corp. | 0001144204-18-042170 ↗ |
| 2018-08-16 | S-1/A | S-1/A (amendment) | Tenzing Acquisition Corp. | 0001144204-18-045184 ↗ |
| 2018-08-20 | S-1MEF | S-1MEF (added securities) | Tenzing Acquisition Corp. | 0001144204-18-045650 ↗ |
| 2018-08-20 | EFFECT | EFFECT (declared effective) | Tenzing Acquisition Corp. | 9999999995-18-002143 ↗ |
| 2018-08-22 | 424B4 | 424B4 (final prospectus) | Tenzing Acquisition Corp. | 0001144204-18-045961 ↗ |
| 2020-11-10 | EFFECT | EFFECT (declared effective) | Tenzing Acquisition Corp. | 9999999995-20-003117 ↗ |
| 2020-12-29 | S-1 | S-1 (registration) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001104659-20-140190 ↗ |
| 2021-01-07 | S-1/A | S-1/A (amendment) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001104659-21-002049 ↗ |
| 2021-01-11 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-21-000114 ↗ |
| 2021-01-12 | 424B4 | 424B4 (final prospectus) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001104659-21-003280 ↗ |
| 2021-03-26 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-21-001159 ↗ |
| 2021-03-29 | 424B4 | 424B4 (final prospectus) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-21-007450 ↗ |
| 2021-04-19 | S-1 | S-1 (registration) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-21-009169 ↗ |
| 2021-05-10 | S-1/A | S-1/A (amendment) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-21-011438 ↗ |
| 2021-05-14 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-21-001938 ↗ |
| 2021-05-17 | 424B4 | 424B4 (final prospectus) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-21-012528 ↗ |
| 2021-05-19 | S-1/A | S-1/A (amendment) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-21-012734 ↗ |
| 2021-05-25 | S-1/A | S-1/A (amendment) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-21-013217 ↗ |
| 2021-05-26 | S-1MEF | S-1MEF (added securities) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-21-013452 ↗ |
| 2021-05-26 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-21-002120 ↗ |
| 2021-05-28 | 424B4 | 424B4 (final prospectus) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-21-013719 ↗ |
| 2022-02-02 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-22-000312 ↗ |
| 2022-03-22 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-22-000684 ↗ |
| 2022-03-22 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-22-000685 ↗ |
| 2022-10-06 | S-1 | S-1 (registration) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-22-023768 ↗ |
| 2022-10-17 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-22-003060 ↗ |
| 2022-10-18 | 424B4 | 424B4 (final prospectus) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-22-024273 ↗ |
| 2023-04-04 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-23-000816 ↗ |
| 2024-02-13 | 424B4 | 424B4 (final prospectus) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 0001437749-24-003937 ↗ |
| 2024-02-13 | EFFECT | EFFECT (declared effective) | REVIVA PHARMACEUTICALS HOLDINGS, INC. | 9999999995-24-000430 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-08-16 | S-1/A | registration statement | $10.00 | 5,000,000 | $50,000,000 | Nasdaq TZAC | 1 | primary document; price sentence, shares headline, proceeds table, cover names 1 | document ↗ | |
| 2018-08-22 | 424B4 | final prospectus | $10.00 | 5,500,000 | $55,000,000 | Nasdaq TZAC | 1 | primary document; price sentence, shares headline, proceeds table, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Agarrwal Atanuu | Officer | Vice President | 1 | 2018 | |
| CAMPBELL WILLIAM I | Director | 1 | 2018 | ||
| Cordova Gonzalo | Officer | Chief Financial Officer | 1 | 2018 | |
| Nayar Rahul | Director,Officer,TenPercentOwner; TenPercentOwner | Chief Executive Officer | 5 | 2018–2020 | |
| SAXENA PARAG | Director; Director,Officer,TenPercentOwner; Director,TenPercentOwner; TenPercentOwner | Chairman of the Board | 14 | 2018–2025 | |
| Shapiro Nina B. | Director | 1 | 2018 | ||
| Tenzing LLC | Director,TenPercentOwner; TenPercentOwner | 5 | 2018–2020 | ||
| Thapar Vikas | Director | 1 | 2018 | ||
| Gerber Sander | TenPercentOwner | 3 | 2018–2020 | ||
| Hudson Bay Capital Management LP | TenPercentOwner | 3 | 2018–2020 | ||
| MIZUHO SECURITIES USA LLC | TenPercentOwner | 2 | 2020 | ||
| GLAZER CAPITAL, LLC | TenPercentOwner | 14 | 2020 | ||
| GLAZER PAUL J | TenPercentOwner | 14 | 2020 | ||
| Bhat Laxminarayan | Director,Officer; Director,Officer,TenPercentOwner | President and CEO | 5 | 2020–2026 | |
| Cantillon Marc | Officer | Chief Medical Officer | 1 | 2020 | |
| Funtleyder Leslie D. | Director | 7 | 2020–2025 | ||
| Margolin Richard A | Director | 7 | 2020–2025 | ||
| Narayan Prabhu | Officer | Chief Financial Officer | 8 | 2020–2026 | |
| Patel Purav | Director | 9 | 2020–2025 | ||
| BETA OPERATORS FUND, L.P. | TenPercentOwner | 3 | 2021–2022 | ||
| VEDANTA ASSOCIATES, L.P. | TenPercentOwner | 4 | 2021–2023 | ||
| Vedanta Associates-R, LP | TenPercentOwner | 3 | 2021–2022 | ||
| VEDANTA PARTNERS, LLC | TenPercentOwner | 4 | 2021–2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-09-19 | REVIVA PHARMACEUTICALS HOLDINGS, INC. | Pharmaceuticals | Indefinite | $0 | 3 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | REVIVA PHARMACEUTICALS HOLDINGS INC | CA | State business registries | name and state |
| Form D issuer | REVIVA PHARMACEUTICALS HOLDINGS, INC. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | REVIVA PHARMACEUTICALS HOLDINGS, INC. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.